Redeye updates on Zordix ahead of its Q4-results (due 22 February) and following the company’s annou...
Q4 NOI -3% vs ABGSCe Property value changes -1.1%, net LTV 51.
Redeye retains its positive view of Transtema and foresees a strong 2023 fueled by organic and acqui...
2022 a year to forget, but no disaster China re-opening, expanding to India Renewed focus on US prot...
8% EBIT miss, but new, forward-leaning 2025 targets Still solid demand: '23e-'24e EBIT up by 15-21% ...
Investors House reported Q4 revenue of EUR 2.1m, 4% above our estimate, and net operating income (NO...
Redeye ceases its coverage of Careium due to the end of the contractual period.
Redeye updates the fair value range after the Q4 report and the share issue.
IRLAB Therapeutics has provided an update on upcoming development milestones for its central nervous...
Redeye comments on Invisio’s Q4-results which came in much stronger than expected as the company end...
Deal with Westinghouse important for Waste Mgmt.First order for SMRs within the F&MT segmentStrong F...
Q4 – fullt fokus på patientrekrytering Ascelia levererade under fredagen en rapport i linje med våra...
Imponerande lönsamhet och stark tillväxt Omsättningen i kvartalet uppgick till 19,8 mkr vs vårt esti...
Siffrorna var i nivå med förväntan Som förväntat var nettoomsättningen låg i Q4’22 och den uppgick t...
Q4: better than expected driven by both revenues and opex StrongPoint reported Q4 revenues of NOK 40...
IRL757 & IRL942 to Ph 1 in YE'23e and H1'24e Pirepemat PD-Falls trial readout delayed to H1'24e IRLA...
Slower revenue development than expected.
Investors House reported Q4 revenues of EUR 2.1m, +4% versus our estimate.
Marimekko reports its Q4 result on Wednesday, 15th of Feb.
Insurtechbolaget Paydrives intäkter ökade till 8,1 (4,4) miljoner kronor under det fjärde kvartalet ...
